Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.
Male hypogonadism is a condition in which the body doesn't produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 5, 4, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism - Overview
Male Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism - Companies Involved in Therapeutics Development
AbbVie Inc
Beijing FuKangren Bio-pharm Tech Co Ltd
Chong Kun Dang Pharmaceutical Corp
Diurnal Group Plc
Endoceutics Inc
Function Promoting Therapies LLC
IASO BioMed Inc
Lennham Pharmaceuticals Inc
Lipocine Inc
M et P Pharma AG
Marius Pharmaceuticals LLC
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
MHB Labs
Solural Pharma ApS
TesoRx Pharma LLC
Transdermal Delivery Solutions Corp
Viramal Ltd
Male Hypogonadism - Drug Profiles
chorionic gonadotropin ER - Drug Profile
Product Description
Mechanism Of Action
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
History of Events
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
History of Events
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
History of Events
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
History of Events
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
History of Events
Libidua - Drug Profile
Product Description
Mechanism Of Action
LPCN-1111 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Block VDAC1 for Hypogonadism - Drug Profile
Product Description
Mechanism Of Action
Rifene - Drug Profile
Product Description
Mechanism Of Action
testosterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone - Drug Profile
Product Description
Mechanism Of Action
testosterone - Drug Profile
Product Description
Mechanism Of Action
testosterone - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone - Drug Profile
Product Description
Mechanism Of Action
testosterone propionate - Drug Profile
Product Description
Mechanism Of Action
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
History of Events
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
History of Events
Male Hypogonadism - Dormant Projects
Male Hypogonadism - Discontinued Products
Male Hypogonadism - Product Development Milestones
Featured News & Press Releases
Mar 02, 2022: Regulatory update on oral native testosterone
Jan 27, 2022: Lipocine announces peer-reviewed publication of phase 3 study results for TLANDO
Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology
Oct 11, 2021: Phase 1 data for DITEST published in European Journal of Endocrinology
Sep 28, 2021: Lipocine announces FDA affirmation of class 1 NDA resubmission for TLANDO
Jun 29, 2021: Acerus announces new PBM contract, significantly expanding NATESTO insurance coverage in the United States
Jun 11, 2021: Marius announces ambulatory blood pressure results published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX
Mar 30, 2021: Acerus announces expansion of NATESTO distribution worldwide
Mar 11, 2021: Marius Pharmaceuticals receives PDUFA date for KYZATREX NDA for treatment of hypogonadism
Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX
Jan 28, 2021: Marius Pharmaceuticals announces Co-CEOs Himanshu H. Shah and Shalin Shah to drive growth ahead of anticipated FDA action of its lead asset, KYZATREX
Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism
Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism
Jan 05, 2021: Marius Pharmaceuticals submits New Drug Application to U.S. FDA for next-generation oral testosterone replacement therapy in male patients with hypogonadism
Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Male Hypogonadism, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Male Hypogonadism - Pipeline by AbbVie Inc, 2022
Male Hypogonadism - Pipeline by Beijing FuKangren Bio-pharm Tech Co Ltd, 2022
Male Hypogonadism - Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
Male Hypogonadism - Pipeline by Diurnal Group Plc, 2022
Male Hypogonadism - Pipeline by Endoceutics Inc, 2022
Male Hypogonadism - Pipeline by Function Promoting Therapies LLC, 2022
Male Hypogonadism - Pipeline by IASO BioMed Inc, 2022
Male Hypogonadism - Pipeline by Lennham Pharmaceuticals Inc, 2022
Male Hypogonadism - Pipeline by Lipocine Inc, 2022
Male Hypogonadism - Pipeline by M et P Pharma AG, 2022
Male Hypogonadism - Pipeline by Marius Pharmaceuticals LLC, 2022
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, 2022
Male Hypogonadism - Pipeline by Merck & Co Inc, 2022
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, 2022
Male Hypogonadism - Pipeline by MHB Labs, 2022
Male Hypogonadism - Pipeline by Solural Pharma ApS, 2022
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, 2022
Male Hypogonadism - Pipeline by Transdermal Delivery Solutions Corp, 2022
Male Hypogonadism - Pipeline by Viramal Ltd, 2022
Male Hypogonadism - Dormant Projects, 2022
Male Hypogonadism - Discontinued Products, 2022
List of Figures
Number of Products under Development for Male Hypogonadism, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
